Product Description
Privigen is an intravenous Ig therapy that contains antibodies—essential proteins in your immune system that identify and destroy bacteria and viruses that cause disease. The primary antibody found in Privigen, immunoglobulin G, is the main type of antibody made by your immune system. (Sourced from: https://www.privigen.com/what-is-privigen/cidp)
Mechanisms of Action: Immunostimulant
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Belgium | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | Indonesia | Ireland | Israel | Italy | Japan | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Netherlands | New Zealand | Norway | Peru | Philippines | Poland | Portugal | Romania | Saudi Arabia | Singapore | Slovakia | Slovenia | Spain | Sweden | Switzerland | Taiwan | Tunisia | Turkey | United Arab Emirates | United Kingdom | United States | Uruguay | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: CSL Behring
Company Location: Eastern America
Company Founding Year: 1904
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Norway
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Small Fiber Neuropathy
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2022-501717-31-00 |
2022-501717-31-00 | P3 |
Not yet recruiting |
Small Fiber Neuropathy |
2027-12-31 |
2025-05-02 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
07/16/2025 |
News Article |
GC Biopharma Presents New Viscosity Research on IVIG Products at ISTH 2025 |
|
10/09/2023 |
News Article |
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Market Revenue, Price, Growth Rate, Forecast To 2031 |
|
07/17/2023 |
News Article |
Intravenous Immunoglobulin Market 2032 As Expanding Steadily Owing to Rising Demand from Expanding Patient Pool |
|
10/14/2022 |
News Article |
Thrombocytopenia Market Insights, Epidemiology and Market Forecasts, 2032 |